RT @montypal: When I approached @ExelixisInc & @genentech, the rationale was straightforward - both #cabozantinib & #atezolizumab had activ…
RT @montypal: When I approached @ExelixisInc & @genentech, the rationale was straightforward - both #cabozantinib & #atezolizumab had activ…
RT @montypal: When I approached @ExelixisInc & @genentech, the rationale was straightforward - both #cabozantinib & #atezolizumab had activ…
RT @montypal: When I approached @ExelixisInc & @genentech, the rationale was straightforward - both #cabozantinib & #atezolizumab had activ…
RT @montypal: When I approached @ExelixisInc & @genentech, the rationale was straightforward - both #cabozantinib & #atezolizumab had activ…
RT @montypal: When I approached @ExelixisInc & @genentech, the rationale was straightforward - both #cabozantinib & #atezolizumab had activ…
RT @montypal: When I approached @ExelixisInc & @genentech, the rationale was straightforward - both #cabozantinib & #atezolizumab had activ…
RT @montypal: When I approached @ExelixisInc & @genentech, the rationale was straightforward - both #cabozantinib & #atezolizumab had activ…
RT @montypal: When I approached @ExelixisInc & @genentech, the rationale was straightforward - both #cabozantinib & #atezolizumab had activ…
RT @montypal: When I approached @ExelixisInc & @genentech, the rationale was straightforward - both #cabozantinib & #atezolizumab had activ…
RT @montypal: When I approached @ExelixisInc & @genentech, the rationale was straightforward - both #cabozantinib & #atezolizumab had activ…
RT @montypal: When I approached @ExelixisInc & @genentech, the rationale was straightforward - both #cabozantinib & #atezolizumab had activ…
RT @montypal: When I approached @ExelixisInc & @genentech, the rationale was straightforward - both #cabozantinib & #atezolizumab had activ…
RT @montypal: When I approached @ExelixisInc & @genentech, the rationale was straightforward - both #cabozantinib & #atezolizumab had activ…
RT @montypal: When I approached @ExelixisInc & @genentech, the rationale was straightforward - both #cabozantinib & #atezolizumab had activ…
When I approached @ExelixisInc & @genentech, the rationale was straightforward - both #cabozantinib & #atezolizumab had activity across many settings & there's rationale for synergy as highlighted by @PauloBergerot et al in his review in @MCT_A
RT @AzadOncology: Thanks @neerajaiims & @montypal for your leadership of this pivotal trial in mCR #ProstateCancer . Compelling pre-clinica…
RT @Silke_Gillessen: I agree with Anthony about the control arm, is a cross-over planned?
I agree with Anthony about the control arm, is a cross-over planned?
RT @AzadOncology: Thanks @neerajaiims & @montypal for your leadership of this pivotal trial in mCR #ProstateCancer . Compelling pre-clinica…
RT @AzadOncology: Thanks @neerajaiims & @montypal for your leadership of this pivotal trial in mCR #ProstateCancer . Compelling pre-clinica…
RT @AzadOncology: Thanks @neerajaiims & @montypal for your leadership of this pivotal trial in mCR #ProstateCancer . Compelling pre-clinica…
RT @AzadOncology: Thanks @neerajaiims & @montypal for your leadership of this pivotal trial in mCR #ProstateCancer . Compelling pre-clinica…
RT @AzadOncology: Thanks @neerajaiims & @montypal for your leadership of this pivotal trial in mCR #ProstateCancer . Compelling pre-clinica…
Thanks @neerajaiims & @montypal for your leadership of this pivotal trial in mCR #ProstateCancer . Compelling pre-clinical (see https://t.co/xX0GtxE0fJ) and clinical rationale for Cabozantinib + Atezolizumab. We have recently opened @PeterMacCC @gu_on
Related #ReviewArticle: Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence. https://t.co/NrvGUqXIQa
@Oncology_Doctor @AdamPhilipStern @NIH @FDAOncology @neerajaiims @DrChoueiri @motzermd @apolo_andrea @TiansterZhang @KidneyCancer @kcCURE @drenriquegrande @Uromigos @kidneycan Good point - would refer you to a manuscript I wrote w @PauloBergerot in @MCT_AA
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @MCT_AACR: #ReviewArticle: Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Ra…
#ReviewArticle: Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence. https://t.co/chkVHOSZi8 https://t.co/6qjYHY5MY6
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
Fantastic explanation of the interaction between anti angiogenesis inhibitors and immunotherapy agents...
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
#ReviewArticle: Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence. https://t.co/L9o5PmO7zQ https://t.co/kle5Cf80Ja
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence. https://t.co/wNGbRUlBCA
Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence | Molecular Cancer Therapeutics https://t.co/OvIOWxtLXn
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @TiansterZhang: Excellent review of the mechanism of cabozantinib enhancing immunotherapy, highlighting the rationale for #kidneycancer…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @TiansterZhang: Excellent review of the mechanism of cabozantinib enhancing immunotherapy, highlighting the rationale for #kidneycancer…
RT @TiansterZhang: Excellent review of the mechanism of cabozantinib enhancing immunotherapy, highlighting the rationale for #kidneycancer…
RT @TiansterZhang: Excellent review of the mechanism of cabozantinib enhancing immunotherapy, highlighting the rationale for #kidneycancer…
RT @TiansterZhang: Excellent review of the mechanism of cabozantinib enhancing immunotherapy, highlighting the rationale for #kidneycancer…
RT @TiansterZhang: Excellent review of the mechanism of cabozantinib enhancing immunotherapy, highlighting the rationale for #kidneycancer…
RT @TiansterZhang: Excellent review of the mechanism of cabozantinib enhancing immunotherapy, highlighting the rationale for #kidneycancer…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @mlazqui: Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clini…
RT @TiansterZhang: Excellent review of the mechanism of cabozantinib enhancing immunotherapy, highlighting the rationale for #kidneycancer…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @TiansterZhang: Excellent review of the mechanism of cabozantinib enhancing immunotherapy, highlighting the rationale for #kidneycancer…
Great read !!
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
Excellent review of the mechanism of cabozantinib enhancing immunotherapy, highlighting the rationale for #kidneycancer COSMIC313 and @ALLIANCE_org 031704 #PDIGREE trials. https://t.co/WRw9Y021KF
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence https://t.co/LTILw2rSrI
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…
RT @neerajaiims: A must read “masterpiece” by @PauloBergerot ... @montypal on current IO landscape of advanced RCC and bladder cancer with…